Aerie Pharmaceuticals, Inc.
Dual mechanism inhibitors for the treatment of disease

Last updated:

Abstract:

Provided are compounds that are inhibitors of both rho kinase and of a monoamine transporter (MAT) act to improve the disease state or condition. Further provided are compositions comprising the compounds. Further provided are methods for treating diseases or conditions, the methods comprising administering compounds according to the invention. One such disease may be glaucoma for which, among other beneficial effects, a marked reduction in intraocular pressure (IOP) may be achieved.

Status:
Grant
Type:

Utility

Filling date:

30 Dec 2019

Issue date:

8 Jun 2021